Barely Significant
← all excerpts

Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review.

Front Oncol · 2022 · PMC9213742 · PMID 35756663

Europe PMCDOI
1
hedged sentence
0.0600
closest p · 1.2× alpha
0.0600
boldest claim

The sentences

borderline significantp=0.06so close (0.05 < p ≤ 0.1)
Of note, the number of oligoprogressive lesions requiring treatment and the time between start of abiraterone or enzalutamide and RT treatment were prognostic factors for PCSS on univariate analysis, although the number of lesions treated was only borderline significant on multivariate analysis (p=0.06).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.